7-amino-8-ethyl-1,2,4,5-tetrahydro-3-benzazepine-3-carboxylic acid tert-butyl ester | 583047-15-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 7-amino-8-ethyl-1,2,4,5-tetrahydro-3-benzazepine-3-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 7-amino-8-ethyl-1,2,4,5-tetrahydro-3-benzazepine-3-carboxylate
• CAS: 583047-15-8
• 化学式: C₁₇H₂₆N₂O₂
• 分子量: 290.406
• InChiKey: HNYHXUOKEMFCSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  7-nitro-8-vinyl-1,2,4,5-tetrahydrobenzo[d]azepine-3-carboxylic acid tert-butyl ester 在 palladium 10% on activated carbon 氢气 作用下， 以 乙醇 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 生成 7-amino-8-ethyl-1,2,4,5-tetrahydro-3-benzazepine-3-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] DOPAMINE RECEPTOR MODULATORS AS ANTIPSYCHOTIC AGENTS
  [FR] MODULATEURS DES RECEPTEURS DE DOPAMINE UTILISES COMME AGENTS ANTIPSYCHOTIQUES

  摘要：

  该发明提供了以下化合物的结构（I）： 其中A和B分别代表基团-(CH2)m-和-(CH2)n-；R1代表氢或C1-6烷基；R2代表氢、卤素、羟基、氰基、硝基、羟基C1-6烷基、三氟甲基、三氟甲氧基、C1-6烷基、C1-6烷氧基、C1-6氟烷氧基、-(CH2)pC3-6环烷基、-(CH2)pOC3-6环烷基、-COC1-6烷基、-SO2C1-6烷基、-SOC1-6烷基、-S-C1-6烷基、-CO2C1-6烷基、-CO2NR7R8、-SO2NR7R8、-(CH2)pNR7R8、-(CH2)pNR7COR8、可选择地取代的芳基、可选择地取代的杂芳基或可选择地取代的杂环烷基；R3代表氢或C1-6烷基；R4代表可选择地取代的芳基或可选择地取代的杂芳基；R5和R6分别独立地代表氢、卤素、羟基、氰基、硝基、羟基C1-6烷基、三氟甲基、三氟甲氧基、C1-6烷基、C1-6烷氧基、-(CH2)pC3-6环烷基、-(CH2)pOC3-6环烷基、-COC1-6烷基、-SO2C1-6烷基、-SOC1-6烷基、-S-C1-6烷基、-CO2C1-6烷基、-CO2NR7R8、-SO2NR7R8、-(CH2)pNR7R8、-(CH2)pNR7COR8、可选择地取代的芳基、可选择地取代的杂芳基或可选择地取代的杂环烷基；R7和R8分别独立地代表氢、C1-6烷基或与它们连接的氮或其他原子一起形成氮杂环烷基环或氧代取代的氮杂环烷基环；m和n分别独立地代表1和2中选择的整数；p独立地代表0、1、2和3中选择的整数；并且：Z代表-CR9R10X-或-XCR9R10-，X代表氧、硫、-SO-或-SO2，或Z代表-CONR11-或-NR9CO-，X代表-CH2-、氧、硫、-SO-或-SO2；R9和R10分别独立地代表氢、C1-6烷基或氟代基；R11代表氢或C1-6烷基；或其药学上可接受的盐或溶剂。该发明的化合物在治疗中特别作为抗精神病药物具有用途。

  公开号：

  WO2003095428A1

文献信息

• Benzenesulfonamide derivatives as antipsychotic agents
  申请人：Bromidge Mark Steven

  公开号：US20050222124A1

  公开（公告）日：2005-10-06

  The invention provides compounds of formula (I) wherein A and B represent the groups —(CH 2 ) m - and —(CH 2 ) n -respectively; R 1 represents hydrogen or C 1-6 alkyl; R 2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC 1-6 alkyl, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, C 3-7 cycloalkylC 1-6 alkoxy, —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) p C 3-6 cycloalkyloxy, —COC 1-6 alkyl, —SO 2 C 1-6 alkyl, —SOC 1-6 alkyl, —S—C 1-6 alkyl, C 1-6 alkylsulfonyloxy, C 1-6 alkylsulfonylC 1-6 alkyl, —CO 2 C 1-6 alkyl, —CO 2 NR 7 R 8 , —SO 2 NR 7 R 8 , C 1-6 alkylsulfonamido, C 1-6 alkylsulfonamidoC 1-6 alkyl, —(CH 2 ) p NR 7 R 8 , C 1-6 alkylamidoC 1-6 alkyl, —(CH 2 ) p NR 7 COR 8 , arylsulfonyl, arylsulfonyloxy, arylsulfonylC 1-6 alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC 1-6 alkyl, arylcarboxamidoC 1-6 alkyl, aroyl, aroylC 1-6 alkyl, arylC 1-6 alkanoyl, —SO 2 NR 7 R 8 , optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl, or a group CONR 7 R 8 or SO 2 NR 7 R 8 wherein R 7 and R 8 together may be fused to form a 5- 7-membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom; R 3 represents hydrogen or C 1-6 alkyl; Ar represents optionally substituted phenyl or optionally substituted monocyclic heteroaryl group; R 4 represents optionally substituted aryl or optionally substituted heteroaryl; R 7 and R 8 each independently represent hydrogen, C 1-6 alkyl or together form a 5- to 7-membered heterocyclic ring; Z represents a bond, an oxygen atom or C 1-6 alkyl; Y represents hydrogen or C 1-6 alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; q represents an integer from 1 to 3; r represents an integer from 1 to 4; or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful in therapy, in particular as antipsychotic agents.

  本发明提供了化合物的公式（I），其中A和B分别表示基团—（CH2）m-和—（CH2）n-；R1表示氢或C1-6烷基；R2表示氢、卤素、羟基、氰基、硝基、羟基C1-6烷基、三氟甲基、三氟甲氧基、C1-6烷基、C1-6烷氧基、C1-6烷氧基C1-6烷基、C3-7环烷基C1-6烷氧基、—（CH2）pC3-6环烷基、—（CH2）pC3-6环烷氧基、—COC1-6烷基、—SO2C1-6烷基、—SOC1-6烷基、—S—C1-6烷基、C1-6烷基磺酰氧基、C1-6烷基磺酰C1-6烷基、—CO2C1-6烷基、—CO2NR7R8、—SO2NR7R8、C1-6烷基磺酰胺基、C1-6烷基磺酰胺基C1-6烷基、—（CH2）pNR7R8、C1-6烷基酰胺基C1-6烷基、—（CH2）pNR7COR8、芳基磺酰基、芳基磺酰氧基、芳基磺酰C1-6烷基、芳基磺酰胺基、芳基羧酰胺基、芳基磺酰胺基C1-6烷基、芳基羧酰胺基C1-6烷基、芳基、芳基C1-6酰基、—SO2NR7R8、可选择取代的芳基、可选择取代的杂芳基或可选择取代的杂环基，或者是一个CONR7R8或SO2NR7R8基团，其中R7和R8可以共轭形成一个5-7成员的芳香族或非芳香族杂环，该杂环可以被O或S原子打断；R3表示氢或C1-6烷基；Ar表示可选择取代的苯基或可选择取代的单环杂芳基；R4表示可选择取代的芳基或可选择取代的杂芳基；R7和R8各自独立地表示氢、C1-6烷基或共同形成一个5-7成员的杂环；Z表示键，氧原子或C1-6烷基；Y表示氢或C1-6烷基；m和n独立地表示选自1和2的整数；p独立地表示选自0、1、2和3的整数；q表示1至3的整数；r表示1至4的整数；或其药学上可接受的盐或溶剂。这些化合物在治疗中有用，特别是作为抗精神病药物。
• Dopamine receptor modulators as antipsychotic agents
  申请人：Cooper Gwyn David

  公开号：US20070043026A1

  公开（公告）日：2007-02-22

  The invention provides compounds of formula (I): wherein A and B represent the groups —(CH 2 ) m —and —(CH 2 ) n -respectively; R 1 represents hydrogen or C 1-6 alkyl; R 2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC 1-6 alkyl, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy, —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) p OC 3-6 cycloalkyl, —COC 1-6 alkyl, —SO 2 C 1-6 alkyl, —SOC 1-6 alkyl, —S—C 1-6 alkyl, —CO 2 C 1-6 alkyl, —CO 2 NR 7 R 8 , —SO 2 NR 7 R 8 , —(CH 2 ) p NR 7 R 8 —(CH 2 ) p NR 7 COR 8 , optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl; R 3 represents hydrogen or C 1-6 alkyl; R 4 represents optionally substituted aryl or optionally substituted heteroaryl; R 5 and R 6 each independently represent hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC 1-6 alkyl, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) p OC 3-6 cycloalkyl, —COC 1-6 alkyl, —SO 2 C 1-6 alkyl, —SOC 1-6 alkyl, —S—C 1-6 alkyl, —CO 2 C 1-6 alkyl, —CO 2 NR 7 R 8 , —SO 2 NR 7 R 8 , —(CH 2 ) p NR 7 R 8 , —(CH 2 ) p NR 7 COR 8 , optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl; R 7 and R 8 each independently represent hydrogen, C 1-6 alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; and either: Z represents —CR 9 R 10 X— or —XCR 9 R 10 — and X represents oxygen, sulfur, —SO— or —SO 2 , or Z represents —CONR 11 — or —NR 9 CO— and X represents —CH 2 —, oxygen, sulfur, —SO— or —SO 2 ; R 9 and R 10 each independently represent hydrogen, C 1-6 alkyl or fluoro; R 11 represents hydrogen or C 1-6 alkyl; or a pharmaceutically acceptable salt or solvate thereof. The compounds of the invention are useful in therapy, in particular as antipsychotic agents.

  本发明提供了式（I）的化合物：其中A和B分别代表基团—（CH2）m和—（CH2）n；R1代表氢或C1-6烷基；R2代表氢、卤素、羟基、氰基、硝基、羟基C1-6烷基、三氟甲基、三氟甲氧基、C1-6烷基、C1-6烷氧基、C1-6氟烷氧基、—（CH2）pC3-6环烷基、—（CH2）pOC3-6环烷基、—COC1-6烷基、—SO2C1-6烷基、—SOC1-6烷基、—S—C1-6烷基、—CO2C1-6烷基、—CO2NR7R8、—SO2NR7R8、—（CH2）pNR7R8—（CH2）pNR7COR8，可选择取代芳基、可选择取代杂芳基或可选择取代杂环基；R3代表氢或C1-6烷基；R4代表可选择取代的芳基或可选择取代的杂芳基；R5和R6各自独立地代表氢、卤素、羟基、氰基、硝基、羟基C1-6烷基、三氟甲基、三氟甲氧基、C1-6烷基、C1-6烷氧基、—（CH2）pC3-6环烷基、—（CH2）pOC3-6环烷基、—COC1-6烷基、—SO2C1-6烷基、—SOC1-6烷基、—S—C1-6烷基、—CO2C1-6烷基、—CO2NR7R8、—SO2NR7R8、—（CH2）pNR7R8、—（CH2）pNR7COR8，可选择取代芳基、可选择取代杂芳基或可选择取代杂环基；R7和R8各自独立地代表氢、C1-6烷基或与它们附着的氮或其他原子一起形成一个氮杂环烷基或氧代取代的氮杂环烷基环；m和n各自独立地表示从1和2中选择的整数；p独立地表示从0、1、2和3中选择的整数；且：要么：Z表示—CR9R10X—或—XCR9R10—，X表示氧、硫、—SO—或—SO2，或者Z表示—CONR11—或—NR9CO—，X表示—CH2—、氧、硫、—SO—或—SO2；R9和R10各自独立地代表氢、C1-6烷基或氟；R11代表氢或C1-6烷基；或其药学上可接受的盐或溶剂。本发明的化合物在治疗中有用，特别是作为抗精神病药物。
• BENZENESULFONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1474399A1

  公开（公告）日：2004-11-10
• DOPAMINE RECEPTOR MODULATORS AS ANTIPSYCHOTIC AGENTS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1503989A1

  公开（公告）日：2005-02-09
• [EN] BENZENESULFONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS<br/>[FR] DERIVES BENZENESULFONAMIDE UTILISES COMME ANTIPSYCHOTIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2003068752A1

  公开（公告）日：2003-08-21

  The invention provides compounds of formula (I)wherein A and B represent the groups -(CH2)m- and -(CH2)n-respectively; R1 represents hydrogen or C1-6alkyl; R2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC1-6alkyl, trifluoromethyl, trifluoromethoxy, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C3-7cycloalkylC1-6alkoxy, -(CH2)pC3-6cycloalkyl, -(CH2)pC3-6cycloalkyloxy, -COC1-6alkyl, -SO2C1-6alkyl, -SOC1-6alkyl, -S-C1-6alkyl, C1-6alkylsulfonyloxy, C1-6alkylsulfonylC1-6alkyl, -CO2C1-6alkyl, -CO2NR7R8, -SO2NR7R8, C1-6alkylsulfonamido, C1-6alkylsulfonamidoC1-6alkyl, -(CH2)pNR7R8, C1-6alkylamidoC1-6alkyl, -(CH2)pNR7COR8, arylsulfonyl, arylsulfonyloxy, arylsulfonylC1-6alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC1-6alkyl, arylcarboxamidoC1-6alkyl, aroyl, aroylC1-6alkyl, arylC1-6alkanoyl, -SO2NR7R8, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl, or a group CONR7R8 or SO2NR7R8 wherein R7 and R8 together may be fused to form a 5- 7-membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom; R3 represents hydrogen or C1-6alkyl; Ar represents optionally substituted phenyl or optionally substituted monocyclic heteroaryl group; R4 represents optionally substituted aryl or optionally substituted heteroaryl; R7 and R8 each independently represent hydrogen, C1-6alkyl or together form a 5- to 7-membered heterocyclic ring; Z represents a bond, an oxygen atom or C1-6alkyl:Y represents hydrogen or C1-6alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; q represents an integer from 1 to 3; r represents an integer from 1 to 4; or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful in therapy, in particular as antipsychotic agents.